Auto T cells that fight cancer show promising results for severe tumor treatment

Clinical trial that uses Designed immune cells Cancer hunting reported impressive results for solid tumors, a type of cancer that is difficult to treat. Compared to standard treatments, immunotherapy has extended the survival of people with cancer¹.

Clinical Testing Phase II in China tested the t-brinks of Hymer antigens (Emperor) in people with advanced gastric cancer or gastroesophageal cancer, which are Solid tumors. To create the therapy of the Car-T-Stanica, T cells are collected from a person with cancer and are touched to create proteins that target cancer cells. T cells are then poured back into the same person. Therapy of the Car-T-Stanica revolutionized the treatment of cancer but was the highest Successful against blood cancer.

“Solid tumors generally do not respond to the therapy of Car-T-Stanic,” says Lisa Mielke, a cancer researcher of Cancer Research Institute Olivia Newton John in Heidelberg, Australia. Tests are among the first in which the therapy of the Car-T-Stanica had promising results against solid tumors. They provide “evidence that there is a potential that Emperor T cells are further optimized for future treatment of patients with solid tumors,” Mielke adds.

The last means

Treatment, named Saunricabtagena Autoleucel (SATRI-CEL), targets CLDN18.2, molecules expressed in large quantities in gastrointestinal tumors.

The examination included 156 participants, aged 18 to 75, who received at least two unsuccessful treatments for advanced gastric or gastroezophageal cancer and had tumor tumor samples that were positive on CLDN18.2. Satri-CeL received 88 people up to 3 times during the test period, along with a regime that removed nonspecific immune cells to make treatment more effective. The remaining 52 people formed a control group, receiving standard therapies such as levels of levels, paclitaxel or rivockeraniba.

Of the people treated with Satri-Cele, 35% responded to it, compared to only 4% of people who received standard care. Those who received the therapy of the Car-T-Stanica also lived an average of 2.4 months longer, and 31% are less likely to die from people in the control group.